JP2023521674A - 生理学的状態を治療するための非侵襲的な集束させた超音波の神経調節 - Google Patents
生理学的状態を治療するための非侵襲的な集束させた超音波の神経調節 Download PDFInfo
- Publication number
- JP2023521674A JP2023521674A JP2022560366A JP2022560366A JP2023521674A JP 2023521674 A JP2023521674 A JP 2023521674A JP 2022560366 A JP2022560366 A JP 2022560366A JP 2022560366 A JP2022560366 A JP 2022560366A JP 2023521674 A JP2023521674 A JP 2023521674A
- Authority
- JP
- Japan
- Prior art keywords
- interest
- dss
- region
- focused ultrasound
- fus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002604 ultrasonography Methods 0.000 title claims abstract description 113
- 230000004007 neuromodulation Effects 0.000 title claims abstract description 34
- 230000004962 physiological condition Effects 0.000 title 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract description 58
- 238000000034 method Methods 0.000 claims abstract description 47
- 210000003451 celiac plexus Anatomy 0.000 claims abstract description 43
- 210000000609 ganglia Anatomy 0.000 claims abstract description 24
- 230000002093 peripheral effect Effects 0.000 claims abstract description 13
- 238000011282 treatment Methods 0.000 claims description 31
- 230000000638 stimulation Effects 0.000 claims description 26
- 238000003384 imaging method Methods 0.000 claims description 21
- 239000000523 sample Substances 0.000 claims description 18
- 230000008859 change Effects 0.000 claims description 17
- 230000000968 intestinal effect Effects 0.000 claims description 17
- 208000003098 Ganglion Cysts Diseases 0.000 claims description 16
- 208000005400 Synovial Cyst Diseases 0.000 claims description 16
- 230000037361 pathway Effects 0.000 claims description 13
- 230000006872 improvement Effects 0.000 claims description 10
- 230000003393 splenic effect Effects 0.000 claims description 10
- 230000007423 decrease Effects 0.000 claims description 9
- 210000000331 sympathetic ganglia Anatomy 0.000 claims description 7
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 6
- 230000002550 fecal effect Effects 0.000 claims description 6
- 230000004044 response Effects 0.000 claims description 6
- 210000002767 hepatic artery Anatomy 0.000 claims description 5
- 210000002563 splenic artery Anatomy 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 4
- 230000001713 cholinergic effect Effects 0.000 claims description 4
- 210000000702 aorta abdominal Anatomy 0.000 claims description 3
- 230000002440 hepatic effect Effects 0.000 claims description 3
- 210000000118 neural pathway Anatomy 0.000 claims description 3
- 230000010004 neural pathway Effects 0.000 claims description 3
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 2
- 102100032752 C-reactive protein Human genes 0.000 claims description 2
- 102000003814 Interleukin-10 Human genes 0.000 claims description 2
- 108090000174 Interleukin-10 Proteins 0.000 claims description 2
- 102000013462 Interleukin-12 Human genes 0.000 claims description 2
- 108010065805 Interleukin-12 Proteins 0.000 claims description 2
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 claims description 2
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 claims description 2
- 210000003594 spinal ganglia Anatomy 0.000 claims description 2
- 230000036765 blood level Effects 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 214
- 241001465754 Metazoa Species 0.000 description 108
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 64
- 241000700159 Rattus Species 0.000 description 58
- 210000001519 tissue Anatomy 0.000 description 45
- 208000032843 Hemorrhage Diseases 0.000 description 38
- 208000034158 bleeding Diseases 0.000 description 33
- 230000000740 bleeding effect Effects 0.000 description 33
- 208000024891 symptom Diseases 0.000 description 33
- 210000001072 colon Anatomy 0.000 description 28
- 230000035622 drinking Effects 0.000 description 27
- 102000004127 Cytokines Human genes 0.000 description 24
- 108090000695 Cytokines Proteins 0.000 description 24
- 230000000694 effects Effects 0.000 description 22
- 238000011156 evaluation Methods 0.000 description 19
- 208000016261 weight loss Diseases 0.000 description 18
- 230000004580 weight loss Effects 0.000 description 18
- 238000009210 therapy by ultrasound Methods 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 14
- 230000004913 activation Effects 0.000 description 13
- 238000010171 animal model Methods 0.000 description 12
- 230000006870 function Effects 0.000 description 10
- 230000033001 locomotion Effects 0.000 description 10
- 210000000056 organ Anatomy 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000008595 infiltration Effects 0.000 description 8
- 238000001764 infiltration Methods 0.000 description 8
- 210000005036 nerve Anatomy 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 210000000225 synapse Anatomy 0.000 description 8
- 230000008685 targeting Effects 0.000 description 8
- 238000006073 displacement reaction Methods 0.000 description 7
- 230000008378 epithelial damage Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 6
- 230000000112 colonic effect Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 229960002725 isoflurane Drugs 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000000090 biomarker Substances 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 210000004969 inflammatory cell Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000002858 neurotransmitter agent Substances 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 102000008070 Interferon-gamma Human genes 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 244000144993 groups of animals Species 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 230000001766 physiological effect Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 239000008399 tap water Substances 0.000 description 4
- 235000020679 tap water Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000002417 xiphoid bone Anatomy 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 206010038063 Rectal haemorrhage Diseases 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 210000004953 colonic tissue Anatomy 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 210000002175 goblet cell Anatomy 0.000 description 3
- 208000035861 hematochezia Diseases 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 230000030214 innervation Effects 0.000 description 3
- 229960003130 interferon gamma Drugs 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011808 rodent model Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000012285 ultrasound imaging Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 241000209094 Oryza Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 101001069900 Rattus norvegicus Growth-regulated alpha protein Proteins 0.000 description 2
- 108010005246 Tissue Inhibitor of Metalloproteinases Proteins 0.000 description 2
- 102000005876 Tissue Inhibitor of Metalloproteinases Human genes 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 238000003236 bicinchoninic acid assay Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004534 cecum Anatomy 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000009266 disease activity Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 102000009634 interleukin-1 receptor antagonist activity proteins Human genes 0.000 description 2
- 108040001669 interleukin-1 receptor antagonist activity proteins Proteins 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000000713 mesentery Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 210000004126 nerve fiber Anatomy 0.000 description 2
- 230000003227 neuromodulating effect Effects 0.000 description 2
- 230000003957 neurotransmitter release Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 208000037816 tissue injury Diseases 0.000 description 2
- 238000007492 two-way ANOVA Methods 0.000 description 2
- 210000001186 vagus nerve Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000473391 Archosargus rhomboidalis Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 1
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 description 1
- 108700012434 CCL3 Proteins 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- 102000000013 Chemokine CCL3 Human genes 0.000 description 1
- 108010078239 Chemokine CX3CL1 Proteins 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010015084 Episcleritis Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 102000013818 Fractalkine Human genes 0.000 description 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- -1 IL-1β Proteins 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 102100030703 Interleukin-22 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108010092694 L-Selectin Proteins 0.000 description 1
- 102000016551 L-selectin Human genes 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 101000947192 Rattus norvegicus C-X-C motif chemokine 2 Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000002934 adrenergic neuron Anatomy 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000004082 barrier epithelial cell Anatomy 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 229920003045 dextran sodium sulfate Polymers 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000004921 distal colon Anatomy 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 210000005216 enteric neuron Anatomy 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000021824 exploration behavior Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000002599 functional magnetic resonance imaging Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 1
- 239000000859 incretin Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 108010074109 interleukin-22 Proteins 0.000 description 1
- 230000004609 intestinal homeostasis Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000009854 mucosal lesion Effects 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008289 pathophysiological mechanism Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000013105 post hoc analysis Methods 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 210000000063 presynaptic terminal Anatomy 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012764 semi-quantitative analysis Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000001845 splenic macrophage Anatomy 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 230000003685 thermal hair damage Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 230000005944 tissue migration Effects 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000001515 vagal effect Effects 0.000 description 1
- 239000006200 vaporizer Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N7/02—Localised ultrasound hyperthermia
- A61N7/022—Localised ultrasound hyperthermia intracavitary
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/46—Ultrasonic, sonic or infrasonic diagnostic devices with special arrangements for interfacing with the operator or the patient
- A61B8/467—Ultrasonic, sonic or infrasonic diagnostic devices with special arrangements for interfacing with the operator or the patient characterised by special input means
- A61B8/469—Ultrasonic, sonic or infrasonic diagnostic devices with special arrangements for interfacing with the operator or the patient characterised by special input means for selection of a region of interest
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/54—Control of the diagnostic device
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00017—Electrical control of surgical instruments
- A61B2017/00137—Details of operation mode
- A61B2017/00154—Details of operation mode pulsed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/08—Detecting organic movements or changes, e.g. tumours, cysts, swellings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0004—Applications of ultrasound therapy
- A61N2007/0021—Neural system treatment
- A61N2007/0026—Stimulation of nerve tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0052—Ultrasound therapy using the same transducer for therapy and imaging
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Surgical Instruments (AREA)
Abstract
Description
本願は、2020年4月9日に出願された米国仮出願第63/007,766号、および2020年5月20日に出願された米国仮出願第63/027,724号の優先権および利益を主張する。
合計60匹のラットを以下の群に分けた。「DSS」と表示したデキストラン硫酸ナトリウムを飲用している動物。非侵襲的な集束させた超音波を与えられた動物は、「FUS」群である。「偽FUS」とラベル付けされた集束させた超音波のための偽対照群として、ラットは、剃毛された腹部などで集束させた超音波を受け、イソフルランで麻酔されたものと同じ処置を受け、ペンでマークされ、トランスデューサプローブは、剣状突起と下側肋骨との間の同じスポットに配置された。しかしながら、RF電力増幅器、関数発生器、およびトランスデューサはオフにされた。DSSまたは集束させた超音波を与えず、体重の変化を監視し、便の硬さおよび肉眼的出血スコアを評価するために1日1回だけケージから取り出した動物を「ナイーブ」と表した。1日2回の非侵襲的な集束させた超音波を受けた動物は、処置命名前に「2×」と示された。「2×FUS」群の動物に特異的に、ラットは、第1の集束させた超音波のセッションの約6時間後の午前中に第1の集束させた超音波セッションを行い、午後に第2の集束させた超音波セッションを行って、毎日2回の集束させた超音波処置を受けた。第2の集束させた超音波の設定は、午前中に行われた第1の集束させた超音波と同一であったが、第2の集束させた超音波処置中にエンドポイントのメトリックは収集されなかった。いくつかの動物群についても、複数の処置を受けることを反映させるために標識を組み合わせた。例えば、DSSを飲用しているが、毎日2回の偽集束の超音波処置を受けているラットは、「DSS+2×偽FUS」と表された。
Claims (22)
- 方法であって、
1つまたは複数の神経経路の神経調節を誘導するために、対象の関心領域に集束させた超音波エネルギーを適用することであって、前記関心領域が腹腔神経叢の少なくとも一部を含む、適用することを含む、方法。 - 腹部大動脈との肝動脈および/または脾動脈の接合部を識別するために前記対象の内部組織を撮像すること、および
前記関心領域を前記接合部に隣接するように選択すること、をさらに含む、請求項1に記載の方法。 - 前記関心領域が、前記対象の末梢神経節、上腸間膜神経節、腹腔神経節、下腸間膜神経節、または後根神経節を含む、請求項1に記載の方法。
- 前記関心領域が、上腸間膜神経節および左右の腹腔神経節の近位の前迷走神経幹を含む、請求項1に記載の方法。
- 前記対象が炎症性腸疾患を有する対象であり、集束させた前記超音波エネルギーを適用することが前記炎症性腸疾患を治療する、請求項1に記載の方法。
- 前記対象がクローン病の診断を有する、請求項5に記載の方法。
- 前記対象が潰瘍性大腸炎の診断を有する、請求項5に記載の方法。
- 前記関心領域に集束させた前記超音波エネルギーを適用することは、ベースラインDAIスコアと比較して前記対象のDAIスコアの改善をもたらし、前記ベースラインDAIスコアは、前記適用することの前に判定される、請求項1に記載の方法。
- 前記関心領域に集束させた前記超音波エネルギーを適用することは、前記適用することの前に判定されたベースライン便血中レベルと比較して便血中レベルの低下をもたらす、請求項1に記載の方法。
- 集束させた前記超音波エネルギーを前記関心領域に適用することにより、ベースライン濃度に対する前記対象の1つまたは複数の関心分子の濃度の変化がもたらされ、前記濃度の変化を検出することをさらに含む、請求項1に記載の方法。
- 前記1つまたは複数の関心分子が、核周囲抗好中球抗体、抗サッカロミセス・セレビシエ抗体、カルプロテクチン、C反応性タンパク質または抗フラジェリン抗体を含む、請求項10に記載の方法。
- 集束させた前記超音波エネルギーを前記関心領域に適用することが、腸コリン作動性抗炎症経路(CAP)の刺激を引き起こす、請求項1に記載の方法。
- 前記関心領域に集束させた前記超音波エネルギーを適用することが、脾臓CAP刺激を引き起こさないか、または腸CAP刺激と比較して比較的少ない脾臓CAP刺激を引き起こす、請求項12に記載の方法。
- 一定期間にわたって集束させた前記超音波エネルギーに対する応答を評価すること、および前記評価することに基づいて投与頻度を変更するように治療プロトコルを変更することとを含む、請求項1に記載の方法。
- システムであって、
対象の腹腔神経叢の末梢神経節を神経調節するために、前記対象の前記腹腔神経叢の少なくとも一部を含む関心領域に、集束させた超音波エネルギーを適用するように構成される超音波プローブ、および
コントローラであって、
撮像モードで動作する前記超音波プローブから前記対象の画像データを取得し、
前記画像データに基づいて前記関心領域を選択し、
前記対象の炎症性腸疾患を治療するための治療プロトコルの一部として、前記関心領域に集束させた前記超音波エネルギーを適用するように前記超音波プローブを制御するよう構成されるコントローラを含む、システム。 - 前記超音波トランスデューサは、集束させた前記超音波エネルギーを適用するように構成される治療トランスデューサと、前記画像データを取得するように構成される撮像プローブとを含む、請求項15に記載のシステム。
- 前記関心領域が、前記腹腔神経叢の末梢神経節の少なくとも一部を含む、請求項15に記載のシステム。
- 前記治療プロトコルが、複数の日にわたって少なくとも毎日、前記関心領域に前記超音波エネルギーを適用することを含む、請求項15に記載のシステム。
- 前記コントローラは、
前記画像データを表示させ、
表示された前記画像データ内の前記関心領域を示すユーザ入力を受け取り、
前記ユーザ入力に基づいて前記関心領域を選択するように構成される、請求項15に記載のシステム。 - 方法であって、
撮像モードで動作する超音波プローブから対象の画像データを取得することであって、前記対象が炎症性腸疾患と診断される、取得すること、
前記画像データに基づいて、前記腹腔神経叢の少なくとも一部を含む関心領域を選択すること、および
前記炎症性腸疾患を治療するための治療プロトコルの一部として、前記関心領域に集束させた超音波エネルギーを適用するように前記超音波プローブを制御することであって、前記関心領域が腹腔神経叢の末梢神経節の少なくとも一部を含む、制御することを含む、方法。 - 集束させた前記超音波エネルギーを前記関心領域に適用することにより、ベースライン濃度に対する前記対象の1つまたは複数の関心分子の濃度の変化がもたらされ、前記濃度の変化を検出することをさらに含む、請求項20に記載の方法。
- 前記1つまたは複数の関心分子が、IL-12、IL-23、TNF、TGF、またはIL-10のうちの1つまたは複数を含む、請求項21に記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063007766P | 2020-04-09 | 2020-04-09 | |
US63/007,766 | 2020-04-09 | ||
US202063027724P | 2020-05-20 | 2020-05-20 | |
US63/027,724 | 2020-05-20 | ||
PCT/US2021/025922 WO2021207161A1 (en) | 2020-04-09 | 2021-04-06 | Non-invasive focused ultrasound neuromodulation to treat physiological conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2023521674A true JP2023521674A (ja) | 2023-05-25 |
Family
ID=78023448
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022560366A Pending JP2023521674A (ja) | 2020-04-09 | 2021-04-06 | 生理学的状態を治療するための非侵襲的な集束させた超音波の神経調節 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20230140990A1 (ja) |
EP (1) | EP4132645A4 (ja) |
JP (1) | JP2023521674A (ja) |
CN (1) | CN115666719A (ja) |
WO (1) | WO2021207161A1 (ja) |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7510536B2 (en) * | 1999-09-17 | 2009-03-31 | University Of Washington | Ultrasound guided high intensity focused ultrasound treatment of nerves |
US8469904B2 (en) * | 2009-10-12 | 2013-06-25 | Kona Medical, Inc. | Energetic modulation of nerves |
US20160059044A1 (en) * | 2009-10-12 | 2016-03-03 | Kona Medical, Inc. | Energy delivery to intraparenchymal regions of the kidney to treat hypertension |
WO2014013285A1 (en) * | 2012-07-16 | 2014-01-23 | Super Sonic Imagine | Apparatus and method for determining optimal positions of a hifu probe |
US20150223877A1 (en) * | 2014-02-12 | 2015-08-13 | Perseus-Biomed Inc. | Methods and systems for treating nerve structures |
EP3226795B1 (en) * | 2014-12-03 | 2020-08-26 | Metavention, Inc. | Systems for modulating nerves or other tissue |
WO2018022902A1 (en) * | 2016-07-27 | 2018-02-01 | The Trustees Of Columbia University In The City Of New York | Methods and systems for peripheral nerve modulation using focused ultrasound |
AU2017348440C1 (en) * | 2016-10-31 | 2023-07-20 | General Electric Company | Techniques for neuromodulation |
US20190269942A1 (en) * | 2018-03-05 | 2019-09-05 | Medtronic, Inc. | Ultrasound therapy for bladder dysfunction |
CN112088032A (zh) * | 2018-03-09 | 2020-12-15 | 通用电气公司 | 神经调节技术 |
US11235178B2 (en) * | 2018-09-04 | 2022-02-01 | General Electric Company | Neuromodulation energy application techniques |
-
2021
- 2021-04-06 US US17/917,539 patent/US20230140990A1/en active Pending
- 2021-04-06 WO PCT/US2021/025922 patent/WO2021207161A1/en unknown
- 2021-04-06 JP JP2022560366A patent/JP2023521674A/ja active Pending
- 2021-04-06 CN CN202180040723.2A patent/CN115666719A/zh active Pending
- 2021-04-06 EP EP21784053.7A patent/EP4132645A4/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230140990A1 (en) | 2023-05-11 |
WO2021207161A1 (en) | 2021-10-14 |
EP4132645A4 (en) | 2024-04-17 |
CN115666719A (zh) | 2023-01-31 |
EP4132645A1 (en) | 2023-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7278948B2 (ja) | 神経調節のための技術 | |
US11013938B2 (en) | Methods and systems for peripheral nerve modulation using non ablative focused ultrasound with electromyography (EMG) monitoring | |
CN109069824B (zh) | 使用深部脑刺激治疗自身免疫疾病 | |
US20220040483A1 (en) | Vagus nerve stimulation pre-screening test | |
KR20180040516A (ko) | 신경조절 장치 | |
US20150224345A1 (en) | Acoustic shock wave therapeutic methods | |
US20220031563A1 (en) | Treatments for blood sugar levels and muscle tissue optimization using extracorporeal acoustic shock waves | |
JP7404254B2 (ja) | 超音波ニューロモジュレーション技術 | |
JP7478475B2 (ja) | 認知症を治療するための装置、当該装置の作動方法及びプログラム | |
JP2023058664A (ja) | ニューロモジュレーション技術 | |
Akhtar et al. | Non‐invasive peripheral focused ultrasound neuromodulation of the celiac plexus ameliorates symptoms in a rat model of inflammatory bowel disease | |
Niu et al. | Noninvasive ultrasound deep brain stimulation of nucleus accumbens induces behavioral avoidance | |
JP2023521674A (ja) | 生理学的状態を治療するための非侵襲的な集束させた超音波の神経調節 | |
US20200147415A1 (en) | Methods and systems for selective modulation of motor neuronal activity in the peripheral nervous system | |
JP7483694B2 (ja) | 神経調節技術 | |
US11083892B2 (en) | Systems and methods for percutaneous nerve stimulation | |
JP2023516545A (ja) | 神経調節のための非侵襲的な組織の移動の制御およびモニタリング | |
JP2022523938A (ja) | 標的グルコース輸送体及び/又はインクレチン経路へのニューロモデュレーション | |
Vion | Study of the Mechanisms Underlying Neurostimulation Induced by Low-Energy Pulsed Ultrasound: Towards Approaches for the Management of Cancer-Related Chronic Pain | |
Dziadoń | INFLUENCE OF VISCERAL TECHNIQUES ON SEROTONIN LEVEL IN THE BLOOD ANALYSIS: A PHASE 0 PLACEBO CONTROLLED BLINDED STUDY | |
Dedeurwaerdere | Neuromodulation in Experimetal Animal Models of Epilepsy | |
WO2022087232A1 (en) | Systems and methods for treating gastrointestinal dysmotility | |
RU2285552C2 (ru) | Способ лечения алкоголизма | |
CN106667988A (zh) | 法尼基转移酶抑制剂在制备易化胆碱能神经系统药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20221222 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230607 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20230607 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230929 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230926 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20231107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20231108 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240109 |